Jennifer Vidler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer Vidler has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
- Austin Kulasekararaj
King's College Hospital NHS Foundation Trust Haematology London UK
15 shared publications - Duncan R. McKenzie
The Francis Crick Institute, London, UK
15 shared publications - Katie Doores
Department of Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London, London, UK
15 shared publications - Piers E. M. Patten
Comprehensive Cancer Centre, King’s College London, London, United Kingdom
15 shared publications - Sheeba Irshad
King’s College London 6 Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences London, United Kingdom
15 shared publications - Thanussuyah Alaguthurai
Department of Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
15 shared publications
Latest Publications
- Open Access
- 27 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (15) , 5285-5292
Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study
Pure red cell aplasia (PRCA) is a rare single lineage bone marrow failure defined by anemia with profound reticulocytopenia and severe reduction of erythroid precursors. Clinical spectrum is heterogeneous, and diagnosis often requires extensive evaluation to distinguish primary from secondary causes such as thymoma, autoimmune diseases, T-LGL expansion and MDS, with which differential diagnosis is particularly challening. Evidence guiding management remains limited due to the rarity of the disease and the lack of prospective studies. We conducted a multicenter retrospective analysis of 121 acquired adult PRCA (excluding PVB19-associated PRCA) cases across 14 European centers. Secondary forms accounted for 78% of cases, mostly thymoma (23%) or MDS (21%). In a subset of patients, BM immunohistochemistry demonstrated significant depositions of C3, C4d, IgM, IgG, reducing after immunosuppression. NGS was performed in half of patients 36% of which presented mutations predominantly related to clonal hematopoiesis, except in MDS-associated cases which often carried multiple non-CH mutations. Immunosuppression represented the backbone of therapy: cyclosporine A (CyA) was the most effective agent, with 61% ORR (47% complete) and better outcomes when initiated earlier; mTOR inhibitors showed promising activity as second-line therapy, with responses in 71% of patients, including CyA-refractory cases. Mortality reached 30%, predominantly due to infectious complications, and was significantly higher in MDS-associated cases. PRCA remains a diagnostically challenging and clinically heterogeneous disorder in which integration of molecular analyses may refine diagnostic accuracy and patient stratification. Immunosuppression remains the mainstay of treatment, with CyA being a reliable first-line and mTORi emerging as encouraging rescue options.
- 27 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (15) , 5285-5292
Open AccessClinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study
Pure red cell aplasia (PRCA) is a rare single lineage bone marrow failure defined by anemia with profound reticulocytopenia and severe reduction of erythroid precursors. Clinical spectrum is heterogeneous, and diagnosis often requires extensive evaluation to distinguish primary from secondary causes such as thymoma, autoimmune diseases, T-LGL expansion and MDS, with which differential diagnosis is particularly challening. Evidence guiding management remains limited due to the rarity of the disease and the lack of prospective studies. We conducted a multicenter retrospective analysis of 121 acquired adult PRCA (excluding PVB19-associated PRCA) cases across 14 European centers. Secondary forms accounted for 78% of cases, mostly thymoma (23%) or MDS (21%). In a subset of patients, BM immunohistochemistry demonstrated significant depositions of C3, C4d, IgM, IgG, reducing after immunosuppression. NGS was performed in half of patients 36% of which presented mutations predominantly related to clonal hematopoiesis, except in MDS-associated cases which often carried multiple non-CH mutations. Immunosuppression represented the backbone of therapy: cyclosporine A (CyA) was the most effective agent, with 61% ORR (47% complete) and better outcomes when initiated earlier; mTOR inhibitors showed promising activity as second-line therapy, with responses in 71% of patients, including CyA-refractory cases. Mortality reached 30%, predominantly due to infectious complications, and was significantly higher in MDS-associated cases. PRCA remains a diagnostically challenging and clinically heterogeneous disorder in which integration of molecular analyses may refine diagnostic accuracy and patient stratification. Immunosuppression remains the mainstay of treatment, with CyA being a reliable first-line and mTORi emerging as encouraging rescue options.
- Open Access
- 25 October 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (21) , 5590-5597
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
Gilteritinib is the current standard of care for relapsed or refractory fms related receptor tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia in many countries, however outcomes for patients relapsing after contemporary first-line therapies (intensive chemotherapy with midostaurin, or nonintensive chemotherapy with venetoclax) are uncertain. Moreover, reported data on toxicity and health care resource use is limited. Here, we describe a large real-world cohort of 152 patients receiving single-agent gilteritinib in 38 UK hospitals. Median age was 61 years, and 36% had received ≥2 prior lines of therapy, including a FLT3 inhibitor in 41% and venetoclax in 24%. A median of 4 cycles of gilteritinib were administered, with 56% of patients requiring hospitalization in the first cycle (median, 10 days). Over half of patients required transfusion in each of the first 4 cycles. Complete remission (CR) was achieved in 21%, and CR with incomplete recovery (CRi) in a further 9%. Remission rates were lower for patients with FLT3–tyrosine kinase domain or adverse karyotype. Day-30 and day-60 mortality were 1% and 10.6%, respectively, and median overall survival was 9.5 months. On multivariable analysis, increasing age, KMT2A rearrangement, and complex karyotype were associated with worse survival whereas RUNX1 mutations were associated with improved survival. Twenty patients received gilteritinib as first salvage having progressed after first-line therapy with venetoclax, with CR/CRi achieved in 25% and median survival 4.5 months. Real-world results with gilteritinib mirror those seen in the clinical trials, but outcomes remain suboptimal, with more effective strategies needed.
- 25 October 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (21) , 5590-5597
Open AccessOutcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
Gilteritinib is the current standard of care for relapsed or refractory fms related receptor tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia in many countries, however outcomes for patients relapsing after contemporary first-line therapies (intensive chemotherapy with midostaurin, or nonintensive chemotherapy with venetoclax) are uncertain. Moreover, reported data on toxicity and health care resource use is limited. Here, we describe a large real-world cohort of 152 patients receiving single-agent gilteritinib in 38 UK hospitals. Median age was 61 years, and 36% had received ≥2 prior lines of therapy, including a FLT3 inhibitor in 41% and venetoclax in 24%. A median of 4 cycles of gilteritinib were administered, with 56% of patients requiring hospitalization in the first cycle (median, 10 days). Over half of patients required transfusion in each of the first 4 cycles. Complete remission (CR) was achieved in 21%, and CR with incomplete recovery (CRi) in a further 9%. Remission rates were lower for patients with FLT3–tyrosine kinase domain or adverse karyotype. Day-30 and day-60 mortality were 1% and 10.6%, respectively, and median overall survival was 9.5 months. On multivariable analysis, increasing age, KMT2A rearrangement, and complex karyotype were associated with worse survival whereas RUNX1 mutations were associated with improved survival. Twenty patients received gilteritinib as first salvage having progressed after first-line therapy with venetoclax, with CR/CRi achieved in 25% and median survival 4.5 months. Real-world results with gilteritinib mirror those seen in the clinical trials, but outcomes remain suboptimal, with more effective strategies needed.
- Top Cited PapersOpen Access
- 23 May 2024
- Published by Elsevier in Blood Neoplasia
- Vol. 1 (3)
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
- 23 May 2024
- Published by Elsevier in Blood Neoplasia
- Vol. 1 (3)
Top Cited PapersOpen AccessReal-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
- Top Cited Papers
- 21 March 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (12) , 1157-1166
Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic disorder that occurs on a background of bone marrow failure (BMF). In PNH, chronic intravascular hemolysis causes an increase in morbidity and mortality, mainly because of thromboses. Over the last 20 years, treatment of PNH has focused on the complement protein C5 to prevent intravascular hemolysis using the monoclonal antibody eculizumab and more recently ravulizumab. In the United Kingdom, all patients are under review at 1 of 2 reference centers. We report on all 509 UK patients with PNH treated with eculizumab and/or ravulizumab between May 2002 and July 2022. The survival of patients with eculizumab and ravulizumab was significantly lower than that of age- and sex-matched controls (P = .001). Only 4 patients died of thromboses. The survival of patients with PNH (n = 389), when those requiring treatment for BMF (clonal evolution to myelodysplastic syndrome or acute leukemia or had progressive unresponsive aplastic anemia) were excluded, was not significantly different from that of age- and sex-matched controls (P = .12). There were 11 cases of meningococcal sepsis (0.35 events per 100 patient-years). Extravascular hemolysis was evident in patients who received treatment, with 26.7% of patients requiring transfusions in the most recent 12 months on therapy. Eculizumab and ravulizumab are safe and effective therapies that reduce mortality and morbidity in PNH, but further work is needed to reduce mortality in those with concomitant BMF.
- 21 March 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (12) , 1157-1166
Top Cited PapersTreatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic disorder that occurs on a background of bone marrow failure (BMF). In PNH, chronic intravascular hemolysis causes an increase in morbidity and mortality, mainly because of thromboses. Over the last 20 years, treatment of PNH has focused on the complement protein C5 to prevent intravascular hemolysis using the monoclonal antibody eculizumab and more recently ravulizumab. In the United Kingdom, all patients are under review at 1 of 2 reference centers. We report on all 509 UK patients with PNH treated with eculizumab and/or ravulizumab between May 2002 and July 2022. The survival of patients with eculizumab and ravulizumab was significantly lower than that of age- and sex-matched controls (P = .001). Only 4 patients died of thromboses. The survival of patients with PNH (n = 389), when those requiring treatment for BMF (clonal evolution to myelodysplastic syndrome or acute leukemia or had progressive unresponsive aplastic anemia) were excluded, was not significantly different from that of age- and sex-matched controls (P = .12). There were 11 cases of meningococcal sepsis (0.35 events per 100 patient-years). Extravascular hemolysis was evident in patients who received treatment, with 26.7% of patients requiring transfusions in the most recent 12 months on therapy. Eculizumab and ravulizumab are safe and effective therapies that reduce mortality and morbidity in PNH, but further work is needed to reduce mortality in those with concomitant BMF.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S1. Waning serological responses to SARS-CoV-2 vaccination.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S1. Waning serological responses to SARS-CoV-2 vaccination.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S4. Local and systemic effects reported within 30 days after 3rd dose of COVID-19 vaccine in patients with solid and haematological cancers and healthy controls.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S4. Local and systemic effects reported within 30 days after 3rd dose of COVID-19 vaccine in patients with solid and haematological cancers and healthy controls.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S3. Boosted serological responses and persistent T cell responses following SARS-CoV-2 vaccination dose
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
S3. Boosted serological responses and persistent T cell responses following SARS-CoV-2 vaccination dose